X
Total 959151 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IRCCS Centro San Giovanni di Dio - Fatebenefratelli | Institute that, in addition to operational units of inpatient, day hospital, the psychiatric residential facilities and clinics, also have different organizational units in the form of laboratories, such as genetics, Neurobiology, neuroimaging, neuropsychology and neurophysiology. | ILX:0105719 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Irinotecan | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. Pharmacology: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase). Mechanism of action: Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Phytogenic. Enzyme Inhibitors. Parasympathomimetics. Prodrugs. Radiation-Sensitizing Agents | ILX:0105720 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Iron | ILX:0105721 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Iron Dextran | Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. Pharmacology: Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia. Mechanism of action: After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores. Drug type: Approved. Small Molecule. Drug category: Anti-anemic Agents. Iron Supplement | ILX:0105722 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Irregular duration | A duration which has irregular start and/or end times. | ILX:0105723 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Irregular rhythm | A rhythm quality inhering in a bearer by virtue of lacking pattern. | ILX:0105724 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Irregular sleep pattern | A sleep pattern which has irregular start and/or end times. | ILX:0105725 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Irregular thickness | A thickness which lacks pattern. | ILX:0105726 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Isaacs Syndrome | A rare neuromuscular disorder with onset usually in late childhood or early adulthood, characterized by intermittent or continuous widespread involuntary muscle contractions; FASCICULATION; hyporeflexia; MUSCLE CRAMP; MUSCLE WEAKNESS; HYPERHIDROSIS; TACHYCARDIA; and MYOKYMIA. Involvement of pharyngeal or laryngeal muscles may interfere with speech and breathing. The continuous motor activity persists during sleep and general anesthesia (distinguishing this condition from STIFF-PERSON SYNDROME). Familial and acquired (primarily autoimmune) forms have been reported (MeSH). | ILX:0105727 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Ishihara plates for color blindness | a test for red-green color deficiencies that consists of a number of colored plates, called Ishihara plates, each of which contain a circle of dots appearing randomized in color and size. Within the pattern are dots which form a number visible to those with normal color vision and invisible, or difficult to see, for those with a red-green color vision defect. | ILX:0105728 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Isla magna of Calleja | A profile (typically representing a sequence alignment) derived from a matrix of nucleotide (or amino acid) counts per position that reflects information content at each position. | ILX:0105729 | 8 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Islands of Calleja | Small clusters of granule cells located in the olfactory tubercle and also within the Island of Calleja magna that lies between the septum and the nucleus accumbens | ILX:0105730 | 11 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Islands of Calleja of ABA 2009 | ILX:0105731 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Islands of Calleja of olfactory tubercle | Part of olfactory tubercle defined by dense aggregations of granule cells | ILX:0105732 | 6 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Isobutyl nitrite | A nitrite ester that has formula C4H9NO2. | ILX:0105733 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Isocarboxazid | An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311) Pharmacology: Isocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression. Mechanism of action: Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidaseA (MAO-A) and monoamine oxidaseB (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors. Drug type: Approved. Small Molecule. Drug category: Antidepressants. Antidepressive Agents. Monoamine Oxidase Inhibitors | ILX:0105734 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Isocenter Position | Isocenter coordinates (x,y,z) in the patient based coordinate system described in (mm). | ILX:0105735 | 6 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Isocortex of ABA 2009 | ILX:0105736 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Isocortex of CIVM postnatal rat brain atlas | The isocortex can be easily segmented in the coronal plane with virtually any image contrast. In most places, the border between the isocortex and the rest of the forebrain is defined by a collection of white matter bundles, which have a very different appearance under most MRI contrasts. The border between the isocortex and other parts of the cortex (olfactory cortex, amygdala etc.) is somewhat more difficult. Rostrally, the isocortex and olfactory cortex are divided by the thin rostral extent of the lateral olfactory tract, which appears much darker on T2 MRI. A horizontal line connecting the two rhinal fissures that is slightly convex towards the dorsal surface of brain approximates the dividing line between these two regions of cortex as far caudal as the mamillary bodies. Caudal to the mamillary bodies the dividing line between isocortex and piriform cortex can be defined based on the dorsal extent of later 2 of the piriform cortex, which appears quite dark (high diffusivity) of diffusion-weighted images. At roughly the caudal extent of the amygdala (the posteromedial cortical amygdaloid nucleus) the piriform cortex disappears abruptly giving way to the entorhinal cortex, which we have included in the isocortex. Further caudal, the isocortex is free-floating on all sides, and is only interrupted in its center by the caudal corpus callosum and subiculum, which tend to have a dark border on T2 MRI that contrasts nicely with the pale-appearing cortex. | ILX:0105737 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Isocortex of PHT00 | ILX:0105738 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X